Champions Oncology, Inc. — Form 10-Q Summary
Business context and period: The company develops oncology solutions using its TumorGraft platform. Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. This filing covers the three and six months ended October 31, 2015, compared with the same periods in 2014.
Financial performance
Amounts are in millions of dollars, except per-share data and percentages.
| Metric | Three months ended Oct. 31, 2015 | Three months ended Oct. 31, 2014 | Six months ended Oct. 31, 2015 | Six months ended Oct. 31, 2014 |
|---|---|---|---|---|
| Revenue | $2.971 | $1.882 | $5.793 | $3.793 |
| Operating loss | $(2.493) | $(3.666) | $(5.390) | $(7.387) |
| Net loss | $(2.548) | $(3.078) | $(5.461) | $(6.684) |
| Basic net loss per share | $(0.29) | $(0.55) | $(0.63) | $(1.20) |
| Net cash used in operating activities | Not provided | Not provided | $(5.127) | $(5.247) |
- Quarterly revenue rose 57.9%; six-month revenue rose 52.7%. TOS revenue increased 73.8% for the quarter and 60.7% for six months, while POS revenue increased 7.5% and 22.6%, respectively.
- Quarterly operating loss narrowed 32.0%; six-month operating loss narrowed 27.0%. The company remained loss-making.
- Quarterly TOS gross margin was 41.9% versus 32.9% a year earlier; six-month margin was 36.6% versus 35.9%. POS gross margins remained negative, improving to (16.9%) for the quarter and (26.5%) for six months.
- Research and development and sales and marketing expenses declined; general and administrative expense increased, including higher executive stock compensation and one-time Nasdaq uplisting-related legal and filing costs.
Balance sheet and liquidity
- At October 31, 2015, cash and cash equivalents were $4.157 million, down from $9.357 million at April 30, 2015. Working capital was $3.1 million; total assets were $7.582 million and total liabilities were $3.480 million.
- Six-month operating cash use was $5.127 million; investing cash use was $44,000, mainly for property and equipment; financing cash use was $29,000. Cash declined $5.2 million over the period.
- The filing reports no off-balance-sheet debt or similar obligations. A capital lease had $91,000 of present-value payments remaining, including a $23,000 current portion. No other conventional debt balance is reported.
- Management said cash on hand was expected to fund operations through at least December 31, 2016, but warned that further capital may be needed to continue as a going concern beyond that point.
Changes, outlook, and risks
- Management attributed TOS growth to larger and more numerous bookings, an expanded sales team, and platform growth. POS growth reflected sequencing revenue, partly offset by lower implant and panel revenue.
- Management expects operating losses to continue until revenue grows substantially. If additional financing is unavailable, the company may have to reduce, delay, or eliminate research and development and other activities; equity financing could dilute shareholders, while debt could impose payment obligations and restrictive covenants.
- The risk-factor section says the company may not meet cash requirements beyond May 31, 2016 without external capital, while the liquidity discussion says cash was expected to last through at least December 31, 2016. This difference should be clarified.
- Other unusual items include the August 12, 2015 one-for-twelve reverse stock split and the prior-period warrant fair-value gain; the warrants were reclassified into equity, so the gain did not recur in 2015.
- The company reported no current legal proceedings. Potential registration-rights penalties were not accrued because management did not consider payment probable. The filing identifies no material control deficiencies; management deemed disclosure controls effective.
Key facts for investors to verify
- Whether the stated cash runway is through December 2016 or only to the May 2016 threshold cited in the risk factors, and what financing plans support the outlook.
- Whether TOS bookings and revenue growth can be sustained, and whether POS gross margins can become positive.
- Cash burn, deferred revenue and receivables collection: accounts receivable increased to $1.891 million from $1.060 million, while deferred revenue declined to $1.644 million from $2.009 million.
- Potential dilution: 8,702,237 common shares were outstanding, with 1,977,761 options and 2,109,840 warrants outstanding at October 31, 2015.